Apart from the above, it was also decided that Basic Customs Duty on import of COVID-19 vaccines be also exempted with immediate effect for a period of 3 months
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
The U.S. Development Finance Corporation is funding a substantial expansion of manufacturing capability for BioE, the vaccine manufacturer in India
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
The country has constantly worked with the spirit of public-private partnership
The government has taken all the effective measures to make healthcare affordable
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn
India produces 60% of the world’s vaccine
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
